Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Athira Pharma Inc ATHA

Healthcare
Athira Pharma, Inc. is a late clinical-stage biopharmaceutical company. It focuses on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline consists of both blood brain barrier permeable and peripherally restricted drug candidates for the central nervous system (CNS), peripheral nervous system, and other indications. Its lead candidate... see more

Recent & Breaking News (NDAQ:ATHA)

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Athira Pharma, Inc

Newsfile August 24, 2022

Athira Pharma Reports Second Quarter 2022 Financial Results and Recent Clinical and Corporate Updates

GlobeNewswire August 15, 2022

Athira Pharma Presents Data from ACT-AD Phase 2 Proof-of-Concept Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer's Patients at the Alzheimer's Association International Conference 2022

GlobeNewswire August 3, 2022

Athira Pharma Presents Preclinical Data at the Alzheimer's Association International Conference 2022

GlobeNewswire August 2, 2022

Athira Pharma to Present Clinical and Preclinical Data at Alzheimer's Association International Conference 2022

GlobeNewswire July 25, 2022

Athira Pharma Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer's Disease

GlobeNewswire June 22, 2022

Athira Pharma Announces Formation of Scientific Advisory Board Comprised of Renowned Leaders in Neurology Research

GlobeNewswire June 7, 2022

ATHIRA PHARMA INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Athira Pharma, Inc. - ATHA

Business Wire May 27, 2022

ATHIRA ALERT: Bragar Eagel & Squire, P.C. Is Investigating Athira Pharma, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Business Wire May 20, 2022

Shareholders Approve the Election of All Three Athira Director Nominees at 2022 Annual Meeting

GlobeNewswire May 19, 2022

Athira Issues Statement in Response to Richard A. Kayne's Suspension of His Proxy Contest

GlobeNewswire May 16, 2022

Athira Pharma Presents Preclinical Data at the 2022 Peripheral Nerve Society (PNS) Annual Meeting

GlobeNewswire May 16, 2022

ATHIRA PHARMA INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Athira Pharma, Inc. - ATHA

PR Newswire May 13, 2022

Athira Pharma Reports First Quarter 2022 Financial Results and Provides Pipeline and Business Updates

GlobeNewswire May 12, 2022

Athira Urges Shareholders to Support its Director Nominees at May 19 Annual Meeting

GlobeNewswire May 11, 2022

Athira Pharma Extends Ongoing Open Label Extension Study for LIFT-AD and ACT-AD Clinical Trials of Fosgonimeton (ATH-1017) for Mild to Moderate Alzheimer's Disease

GlobeNewswire May 9, 2022

ATHIRA PHARMA INVESTIGATION CONTINUED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Athira Pharma, Inc. - ATHA

Business Wire May 5, 2022

Leading Independent Proxy Advisory Firm Glass Lewis Recommends that Athira Shareholders Vote "FOR" All of Athira's Highly Qualified Director Nominees

GlobeNewswire May 5, 2022

Athira Mails Letter to Shareholders Emphasizing the Company's Strong Position and Qualified Board as it Enters Pivotal Chapter

GlobeNewswire May 5, 2022

Leading Independent Proxy Advisory Firm ISS Recommends that Athira Shareholders Vote on Athira's WHITE Proxy Card

GlobeNewswire May 4, 2022